Preclinical Imaging Companies

The preclinical imaging market is projected to reach USD 4.39 billion by 2030 from USD 3.53 billion in 2025, at a CAGR of 4.5% from 2025 to 2030. In vivo preclinical imaging involves the visualization of animal models required during life science research studies. This is particularly important to academic researchers and those involved in drug development activities, prior to human trials. During a drug development process, preclinical studies provide vital information about the drug candidate (such as its therapeutic effects, pharmacodynamics profile, and side effects & toxicities). This forms the basis for regulatory approval to initiate a clinical trial on humans. Market growth is primarily driven by factors such as the rising demand for new drug development, innovations in preclinical imaging, and an increasing number of public-private initiatives and funding to support preclinical research. However, strict regulations hinder the market's growth.

The global preclinical imaging market is highly fragmented, with a significant number of global and regional market players. The major players operating in this market are Kub Technologies (US), Medikor (US), Trifoil Imaging (US), Shanghai United Imaging Healthcare Co., Ltd. (China), Cubresa, Inc. (Canada), Berthold Technolgies GmbH & Co. KG (Germany), Miltenyi Biotech GmbH (Germany), Sofie (US), Fujifilm Visual Sonics (Canada), MILABS B.V. (Netherlands), Aspect Imaging Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK), Viewworks (Korea), AI4R (France), Bruker Corporation (US), Revvity, Inc. (US), MR Solutions (UK), and Mediso Ltd. (UK).

To know about the assumptions considered for the study download the pdf brochure

In April 2025, Bruker Corporation (US) introduced a benchtop live single-cell functional analysis system utilizing OEP microfluidics and machine learning automation. It enables the linking of live-cell functional assays to downstream genomic/proteomic analysis, lowering the cost of entry for translational labs in immuno-oncology, cell therapy, and infectious disease research.

In September 2025, Revvity, Inc. (US) launched its Synergy AI software to unify preclinical in vivo imaging analysis across optical, microCT, ultrasound, and other modalities. Using AI-driven segmentation and ROI quantification, it reduces manual effort, improves reproducibility, and increases throughput, enabling researchers to derive faster and more consistent insights.

Bruker Corporation (US)

Bruker Corporation (US) stands out in the preclinical imaging market. The company has a broad portfolio of preclinical imaging systems, comprising optical imaging, micro-MRI, micro-CT, preclinical magnetic particle imaging, and trimodality (PET/SPECT/CT) imaging systems. In order to strengthen its current position and gain a larger share in the global preclinical imaging market, the company primarily focuses on expanding its preclinical imaging product portfolio by launching technologically advanced products in the market. In February 2023, the company launched SKYSCAN 2214 CMOS EDITION, a multiscale X-ray microscope based on nano-CT (computed tomography) for industrial and academic research. The SKYSCAN 2214 platform incorporates the latest scientific CMOS (sCMOS) detector technology and brings cutting-edge X-ray imaging at the highest resolution to the next level. The company also focuses on acquisitions as its key strategy to ensure its growth in the global preclinical imaging market. In February 2024, Bruker acquired Spectral Instruments Imaging. This acquisition fills a gap in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging (PCI) division, broadening its range of preclinical solutions for disease research.

Revvity, Inc. (US)

Revvity specializes in providing comprehensive health science solutions, technologies, expertise, and services that span the entire spectrum, from discovery to development, and diagnosis to treatment. Its areas of expertise include translational multi-omics technologies, biomarker identification, imaging, predictive analytics, screening and diagnosis tools, detection systems, informatics solutions, and more. Its comprehensive portfolio of technologies gives a competitive advantage in the preclinical imaging market. During fiscal year 2023, the company delivered differentiated performance despite market headwinds, demonstrating the strength of the product portfolio, continued innovation, and investments in its people.

Market Ranking

The preclinical imaging market is highly fragmented, with a handful of major players holding a substantial share through their broad modality portfolios and strong research networks. Bruker Corporation leads the market with its comprehensive multimodal imaging platforms, while Revvity and Mediso maintain strong positions through their integrated nuclear and hybrid imaging solutions. FUJIFILM VisualSonics continues to stand out in high-frequency ultrasound and photoacoustic imaging, and companies such as Aspect Imaging, MR Solutions, TriFoil Imaging, MILabs, and Cubresa reinforce the competitive landscape with specialized or hybrid systems tailored to translational research needs. The remaining market share is distributed among regional and emerging vendors, including Berthold Technologies, SOFIE, Iconeus, LI-COR Biotechnology, United Imaging Healthcare, KUB Technologies, Medikors, Vieworks, and AI4R, which further fragments the market and enables smaller players to carve out niche opportunities. Competition remains driven by innovations in multimodal imaging technologies, rising demand for quantitative in vivo data, and the growing emphasis on supporting drug discovery, molecular imaging, and personalized medicine initiatives.

Related Reports:

Preclinical Imaging Market by Product (Optical Imaging (Bioluminescence), Nuclear Imaging (PET, SPECT), MRI, Reagents (Luciferins, Infrared Dyes), Software), Application (Onco, Cardio), End User (Pharma, Biotech, Academic, CRO) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com